ATE229812T1 - Therapeutische verwendung von bpi proteineprodukten bei patienten mit zystischer fibrose - Google Patents

Therapeutische verwendung von bpi proteineprodukten bei patienten mit zystischer fibrose

Info

Publication number
ATE229812T1
ATE229812T1 AT97946427T AT97946427T ATE229812T1 AT E229812 T1 ATE229812 T1 AT E229812T1 AT 97946427 T AT97946427 T AT 97946427T AT 97946427 T AT97946427 T AT 97946427T AT E229812 T1 ATE229812 T1 AT E229812T1
Authority
AT
Austria
Prior art keywords
patients
protein products
cystic fibrosis
therapeutic use
bpi protein
Prior art date
Application number
AT97946427T
Other languages
English (en)
Inventor
Stephen Fitzhugh Carroll
Patrick J Scannon
Patrick D Gavit
Original Assignee
Xoma Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Technology Ltd filed Critical Xoma Technology Ltd
Application granted granted Critical
Publication of ATE229812T1 publication Critical patent/ATE229812T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT97946427T 1996-11-01 1997-10-31 Therapeutische verwendung von bpi proteineprodukten bei patienten mit zystischer fibrose ATE229812T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74298696A 1996-11-01 1996-11-01
PCT/US1997/019850 WO1998019694A1 (en) 1996-11-01 1997-10-31 Therapeutic uses of bpi protein products in cystic fibrosis patients

Publications (1)

Publication Number Publication Date
ATE229812T1 true ATE229812T1 (de) 2003-01-15

Family

ID=24987059

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97946427T ATE229812T1 (de) 1996-11-01 1997-10-31 Therapeutische verwendung von bpi proteineprodukten bei patienten mit zystischer fibrose

Country Status (8)

Country Link
EP (2) EP0938331B1 (de)
JP (1) JP2002509527A (de)
AT (1) ATE229812T1 (de)
AU (1) AU744918B2 (de)
CA (1) CA2270290A1 (de)
DE (1) DE69718047T2 (de)
NZ (1) NZ335401A (de)
WO (1) WO1998019694A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
KR102030572B1 (ko) 2011-04-05 2019-10-10 다나-파버 캔서 인스티튜트 인크. 방사선 완화제 및 방사선 방호제로서의 ｂｐｉ 및 이의 동질체
WO2014070769A1 (en) 2012-10-29 2014-05-08 The University Of North Carolina At Chapel Hill Methods and compositions for treating mucosal tissue disorders
GB201319620D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
GB201319621D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Antimicrobial agents and their use in therapy
CA3024522C (en) 2016-05-31 2024-06-25 Polyphor Ag Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof
KR20230117644A (ko) 2016-11-17 2023-08-08 레노비온, 아이엔씨. 글루타티온 조성물에 의한 호흡기 질환 및 감염 치료
ES3008699T3 (en) 2017-11-17 2025-03-24 Renovion Inc Stable ascorbic acid compositions and methods of using the same
IL313997A (en) 2022-01-04 2024-08-01 Renovion Inc Aqueous solution including glutathione salt

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3946246B2 (ja) * 1993-02-02 2007-07-18 ゾーマ・コーポレイション 殺菌性／浸透性増大タンパク質（Ｂａｃｔｅｒｉｃｉｄａｌ／Ｐｅｒｍｅａｂｉｌｉｔｙ Ｉｎｃｒｅａｓｉｎｇ ｐｒｏｔｅｉｎ：ＢＰＩ）及び界面活性剤を含有する医薬組成物
CA2157925C (en) * 1993-03-12 2000-06-06 Xoma Corporation Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
US5447913A (en) * 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5646114A (en) * 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
US5912228A (en) * 1995-01-13 1999-06-15 Xoma Corporation Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
US5658877A (en) * 1995-05-18 1997-08-19 Wisconsin Alumni Research Foundation Method to treat endotoxin effects by administration of 33 kilodalton phospholipid binding protein

Also Published As

Publication number Publication date
EP1304118A3 (de) 2004-01-14
WO1998019694A1 (en) 1998-05-14
EP1304118A2 (de) 2003-04-23
EP0938331A1 (de) 1999-09-01
AU5159698A (en) 1998-05-29
CA2270290A1 (en) 1998-05-14
JP2002509527A (ja) 2002-03-26
DE69718047D1 (de) 2003-01-30
AU744918B2 (en) 2002-03-07
EP0938331B1 (de) 2002-12-18
NZ335401A (en) 2000-12-22
DE69718047T2 (de) 2003-11-13

Similar Documents

Publication Publication Date Title
GR3035440T3 (en) Therapeutic uses of bpi protein products for human meningococcemia
ATE217787T1 (de) Aerosolformulierungen mit peptiden und proteinen
FI955552L (fi) Adenoviraalisia eläinperäisiä vektoreita ja niiden käyttö geeniterapiassa
DE69323879D1 (de) Herstellung von rekombinanten, menschlichem lactoferrin
ATE306931T1 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
PT749317E (pt) Aplicacoes terapeuticas de produtos dimericos de proteinas bactericidas indutoras da permeabilidade
CY2016003I2 (el) Ρύθμιση επιθηλιακού ιστού με όμοια με σκαντζόχοιρου πολυπεπτίδια, και σχηματισμοί και χρήσεις σχετικά με αυτήν
FI970656A0 (fi) Painonsäätelyaineet, vastaavat nukseiinihapot ja proteiinit ja näiden diagnostiset ja terapeuttiset käytöt
FI951138L (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
ATE257390T1 (de) Verwendung eines bpi proteinproduktes als antithrombotisches mittel
BR9607583B1 (pt) plasmìdios procarióticos recombinantes.
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
ATE273031T1 (de) Aminobiguanide und ihre verwendung zur desinfektion von kontaktlinsen und konservierung von pharmazeutischen zubereitungen
DE69534165D1 (de) Adenovirus mit glutathion peroxydate gene
ATE229812T1 (de) Therapeutische verwendung von bpi proteineprodukten bei patienten mit zystischer fibrose
HUP9800635A2 (hu) In vivo exogén transzfekcióra és expresszióra használható gyógyászati kombináció
EP0744408A3 (de) Das ob Protein der Rhesusaffen und seine DNA
ITMI942663A0 (it) Proteine ricche in idrossiprolina e formulazioni farmaceutiche e cosmetiche che le compongono
IL117466A0 (en) Recombinant viruses expressing lecithin-cholesterol acryltransferase and their use in gene therapy
DE69803925D1 (de) Methode zur kalt-sterilisation von öfen des tunnel-typs im pharmazeutischen bereich und öfen zur anwendung dieser methode
AU3698595A (en) Dna sequence and protein of the non-structural reading frame i of the human parvovirus b19
DE69821227D1 (de) Verwendung von papovavirus kapsid-proteinen zur verabreichung therapeutischen agentien in nervzellen
AU3628697A (en) Lipid-binding proteins and their therapeutic and diagnostic use
HK1021940A (en) Therapeutic uses of bpi protein products in cystic fibrosis patients
DE69825307D1 (de) Verwendung von protein h als zytostattischer wirkstoff

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties